Welcome to Skin cancer and Mesothelioma Cancer

Mesothelioma Cancer, Melanoma Cancer, Mesothelioma, Mesothelioma Lawyer
==================================================================

Tuesday, February 26, 2008

Fwd: House Panel Rejects Last of Va. Anti-smoking Bills



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:07 PM
Subject: House Panel Rejects Last of Va. Anti-smoking Bills
To: mesothelioma77@gmail.com


A last-gasp effort to ban smoking in restaurants and most other public places died Thursday in a House of Delegates subcommittee.

Fri, 15 Feb 2008 03:32:14 GMT

Source: http://www.wjla.com/news/stories/0208/496199.html
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

=========================================================================
 
in another issue about cancer.... in particular about mesothelioma....
 
 

 The 2 surgical procedures used are pleurectomy with decortication and extrapleural pneumonectomy.

Surgical resection has been relied upon because radiation and chemotherapy get hold of been ineffective unequivocal treatments. There are now a number of cancer treatment options open to mesothelioma patients. Extrapleural pneumonectomy for selected victims with very early stage disease may expand recurrence-free survival, but the impact it has on overall survival is unknown at this time.

Mesothelioma diagnosis can be intimidating and can scare a lot of people, but mesothelioma diagnosis may give you a fighting chance if can be diagnose early. So do yourself a favor if you think that what you are suffering from and had worked in an asbestos related workplace.

The purpose of such investigations in mesothelioma diagnosis is to confirm and to determine the type of mesothelioma, to 'stage' the disease (measure how severe it is), and so to assess whether the disease is operable.

 


 

Fwd: High Pathologic Complete Response in HER 2-positive Locally Advanced Breast Cancer after Primary Systemic Chemotherapy with Weekly Docetaxel and Epirubicin.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:07 PM
Subject: High Pathologic Complete Response in HER 2-positive Locally Advanced Breast Cancer after Primary Systemic Chemotherapy with Weekly Docetaxel and Epirubicin.
To: mesothelioma77@gmail.com


[1]Jpn J Clin Oncol. 2008 Feb 12;
Chen SC, Chang HK, Lin YC, Hsueh S, Cheung YC, Leung WM, Tsai CS, Lo YF, Tsai HP, Shen SC, Chen MF

BACKGROUND: To evaluate pathological complete response rate and to identify the predictor of response after primary systemic chemotherapy (PST) with weekly docetaxel and epirubicin for locally advanced breast cancer. METHODS: Sixty-three patients with locally advanced breast cancer received three cycles PST on day 1 and 8 of each 3-week cycle with epirubicin and docetaxel (epirubicin 45 mg/m(2) intravenous bolus, docetaxel 35 mg/m(2) in 100 ml normal saline infused 1 h), followed by surgery and adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil. The pathological complete response was defined as no invasive carcinoma in breast and axillary nodes after PST. RESULTS: The median tumor sizes (by ultrasound) before and after PST were 6.2 and 2.5 cm, respectively. The negative estrogen receptor (ER) by immunochemical stain was found in 33 (52.4%) patients and HER-2/neu-overexperssion in 12 (19.0%) patients. Clinical overall response rate (ORR) was 89% (95% confidence intervals (95% CI: 81-97), including 38% complete response (95% CI: 26-50), sonographical ORR was 97% (95% CI: 93-100). The pathological complete response were found in 11 patients (18%, 95% CI: 9-27), and 15(24%, 95% CI: 13-35) patients achieved breast only pathological complete response. Nine (27.3%) of thirty-three ER (-) patients and 5 (41.7%) of 12 HER2-positive patients achieved pathological complete response. CONCLUSION: PST with weekly docetaxel and epirubicin were well-tolerated and very high pathological complete response rate was achieved in HER-2/neu -overexpression tumors.



___
Source: http://www.hubmed.org/display.cgi?uids=18270380
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: One Million for Meso



----- Forwarded Message ----
From: Search for mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Thursday, February 21, 2008 5:06:45 PM
Subject: One Million for Meso

The Meso Foundation Allocates $1 Million for Research to Stop Asbestos Cancer SANTA BARBARA, Calif., Jan.

Thu, 10 Jan 2008 23:27:51 GMT

___
Source: http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/01-10-2008/0004734595&EDATE=
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Be a better friend, newshound, and know-it-all with Yahoo! Mobile. Try it now.

Fwd: The short, appalling memory of politics



---------- Forwarded message ----------
From: Live Search News: asbestos cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: The short, appalling memory of politics
To: mesothelioma77@gmail.com


Sydney Morning Herald - ... the day before Bob Collins died in the early hours at his Darwin home after months of surgery and treatment for bowel cancer ... Bernie Banton, the anti-asbestos campaigner; and four former Labor MPs, including Collins. The other three: Queensland's Len ...

Sat, 16 Feb 2008 13:15:00 GMT

___
Source: http://www.smh.com.au/news/alan-ramsey/the-short-appalling-memory-of-politics/2008/02/15/1202760598502.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Cholesterol granuloma of the breast with unusual ossification features (osseous metaplasia).



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Cholesterol granuloma of the breast with unusual ossification features (osseous metaplasia).
To: mesothelioma77@gmail.com


[1]Pathol Res Pract. 2008 Feb 12;
Garofalo S, Casolino C, Accurso A, Falleti J

Cholesterol granuloma of the breast is a rare benign condition that can be mistaken for breast cancer. We present a case of a 42-year-old woman who presented with a 1-year history of asymptomatic palpable nodule in the upper external quadrant of the right breast. Mammography and ultrasonography suggested carcinoma, but excisional biopsy revealed cholesterol granuloma with unusual osseous metaplasia. Although reported to occur more frequently in the middle ear and mastoid process, we believe that better awareness of this rare benign condition is most important to avoid misdiagnosis and unnecessary surgery.



___
Source: http://www.hubmed.org/display.cgi?uids=18276082
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Risk Perceptions and Psychosocial Outcomes of Women With Ductal Carcinoma In Situ: Longitudinal Results From a Cohort Study.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:07 PM
Subject: Risk Perceptions and Psychosocial Outcomes of Women With Ductal Carcinoma In Situ: Longitudinal Results From a Cohort Study.
To: mesothelioma77@gmail.com


[1]J Natl Cancer Inst. 2008 Feb 12;
Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E

Background Ductal carcinoma in situ (DCIS) has a generally favorable overall prognosis, with a systemic recurrence rate of approximately 1%, a local recurrence rate after mastectomy of 1%, and a local recurrence rate after breast-conserving treatment of less than 10%. Preliminary studies have suggested that women with DCIS may overestimate their risk of disease recurrence. Few data exist regarding psychosocial outcomes for women with DCIS. Methods Women in Eastern Massachusetts with newly diagnosed DCIS were asked to participate in a longitudinal study of risk perceptions, psychosocial concerns, and health behaviors. Psychosocial outcomes after DCIS diagnosis and risk perceptions were evaluated at enrollment and at 9 and 18 months. All statistical tests were two-sided. Results Four hundred eighty-seven women with DCIS (64% of eligible participants) completed the enrollment survey. Overall quality of life was good among the women surveyed, and the substantial anxiety at enrollment decreased with time (P

___
Source: http://www.hubmed.org/display.cgi?uids=18270338
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Comprehensive Analysis of DNA Repair Gene Variants and Risk of Meningioma.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:07 PM
Subject: Comprehensive Analysis of DNA Repair Gene Variants and Risk of Meningioma.
To: mesothelioma77@gmail.com


[1]J Natl Cancer Inst. 2008 Feb 12;
Bethke L, Murray A, Webb E, Schoemaker M, Muir K, McKinney P, Hepworth S, Dimitropoulou P, Lophatananon A, Feychting M, Lönn S, Ahlbom A, Malmer B, Henriksson R, Auvinen A, Kiuru A, Salminen T, Johansen C, Christensen HC, Kosteljanetz M, Swerdlow A, Houlston R

Background Meningiomas account for up to 37% of all primary brain tumors. Genetic susceptibility to meningioma is well established, with the risk among relatives of meningioma patients being approximately threefold higher than that in the general population. A relationship between risk of meningioma and exposure to ionizing radiation is also well known and led us to examine whether variants in DNA repair genes contribute to disease susceptibility. Methods We analyzed 1127 tagging single-nucleotide polymorphisms (SNPs) that were selected to capture most of the common variation in 136 DNA repair genes in five case-control series (631 case patients and 637 control subjects) from four countries in Europe. We also analyzed 388 putative functional SNPs in these genes for their association with meningioma. All statistical tests were two-sided. Results The SNP rs4968451, which maps to intron 4 of the gene that encodes breast cancer susceptibility gene 1-interacting protein 1, was consistently associated with an increased risk of developing meningioma. Across the five studies, the association was highly statistically significant (trend odds ratio = 1.57, 95% confidence interval = 1.28 to 1.93; P(trend) = 8.95 x 10(-6); P = .009 after adjusting for multiple testing). Conclusions We have identified a novel association between rs4968451 and meningioma risk. Because approximately 28% of the European population are carriers of at-risk genotypes for rs4968451, the variant is likely to make a substantial contribution to the development of meningioma.



___
Source: http://www.hubmed.org/display.cgi?uids=18270339
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 14, 2008 at 11:07 PM
Subject: A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin.
To: mesothelioma77@gmail.com


[1]J Mol Med. 2008 Feb 13;
Verma NK, Dempsey E, Conroy J, Olwell P, McElligott AM, Davies AM, Kelleher D, Butini S, Campiani G, Williams DC, Zisterer DM, Lawler M, Volkov Y

The ordered, directional migration of T-lymphocytes is a key process during immune surveillance, immune response, and development. A novel series of pyrrolo-1,5-benzoxazepines have been shown to potently induce apoptosis in variety of human chemotherapy resistant cancer cell lines, indicating their potential in the treatment of both solid tumors and tumors derived from the hemopoietic system. Pyrrolobenzoxazepine 4-acetoxy-5-(1-naphtyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]-oxazepine (PBOX-15) has been shown to depolymerize tubulin in vitro and in the MCF7 breast cancer cell line. We hypothesized that this may suggest a role for this compound in modulating integrin-induced T-cell migration, which is largely dependent on the microtubule dynamics. Experiments were performed using human T lymphoma cell line Hut78 and peripheral blood T-lymphocytes isolated from healthy donors. We observed that human T-lymphocytes exposed to PBOX-15 have severely impaired ability to polarize and migrate in response to the triggering stimulus generated via cross-linking of integrin lymphocyte function associated antigen-1 receptor. Here, we show that PBOX-15 can dramatically impair microtubule network via destabilization of tubulin resulting in complete loss of the motile phenotype of T-cells. We demonstrate that PBOX-15 inhibitory mechanisms involve decreased tubulin polymerization and its post-translational modifications. Novel microtubule-targeting effects of PBOX-15 can possibly open new horizons in the treatment of overactive inflammatory conditions as well as cancer and cancer metastatic spreading.



___
Source: http://www.hubmed.org/display.cgi?uids=18270678
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 
Subscribe to: Posts (Atom)